Molecular Mechanism in the Disruption of Chronic Traumatic Encephalopathy-Related R3-R4 Tau Protofibril by Quercetin and Gallic Acid: Similarities and Differences.

Chronic traumatic encephalopathy (CTE) is a unique progressive neurodegenerative tauopathy pathologically related to the aggregation of the tau protein to neurofibrillary tangles. Disrupting tau oligomers (protofibril) is a promising strategy to prevent CTE. Quercetin (QE) and gallic acid (GA), two polyphenol small molecules abundant in natural crops, were proved to inhibit recombinant tau and the R3 fragment of human full-length tau in vitro. However, their disruptive effect on CTE-related protofibril and the underlying molecular mechanism remain elusive. Cryo-electron microscopy resolution reveals that the R3-R4 fragment of tau forms the core of the CTE-related tau protofibril. In this study, we conducted extensive all-atom molecular dynamics simulations on CTE-related R3-R4 tau protofibril with and without QE/GA molecules. The results disclose that both QE and GA can disrupt the global structure of the protofibril, while GA shows a relatively strong effect. The binding sites, exact binding patterns, and disruptive modes for the two molecules show similarities and differences. Strikingly, both QE and GA can insert into the hydrophobic cavity of the protofibril, indicating they have the potential to compete for the space in the cavity with aggregation cofactors unique to CTE-related protofibril and thus impede the further aggregation of the tau protein. Due to relatively short time scale, our study captures the early disruptive mechanism of CTE-related R3-R4 tau protofibril by QE/GA. However, our research does provide valuable knowledge for the design of supplements or drugs to prevent or delay the development of CTE.

[1]  F. J. Luque,et al.  Three to Tango: Inhibitory Effect of Quercetin and Apigenin on Acetylcholinesterase, Amyloid-β Aggregation and Acetylcholinesterase-Amyloid Interaction , 2022, Pharmaceutics.

[2]  Bikash R. Sahoo,et al.  Free Gangliosides Can Alter Amyloid-β Aggregation. , 2022, The journal of physical chemistry letters.

[3]  O. Rolinski,et al.  Impact of the Flavonoid Quercetin on β-Amyloid Aggregation Revealed by Intrinsic Fluorescence , 2022, The journal of physical chemistry. B.

[4]  Hope Pan,et al.  De novo designed protein inhibitors of amyloid aggregation and seeding , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Derreumaux,et al.  Molecular Dynamics Simulations of the Tau Amyloid Fibril Core Dimer at the Surface of a Lipid Bilayer Model: I. In Alzheimer's Disease. , 2022, The journal of physical chemistry. B.

[6]  P. Derreumaux,et al.  Molecular Dynamics Simulations of the Tau R3-R4 Domain Monomer in the Bulk Solution and at the Surface of a Lipid Bilayer Model. , 2022, The journal of physical chemistry. B.

[7]  Yuejuan Zheng,et al.  Quercitrin improved cognitive impairment through inhibiting inflammation induced by microglia in Alzheimer’s disease mice , 2022, Neuroreport.

[8]  S. Perrett,et al.  Distinct lipid membrane-mediated pathways of Tau assembly revealed by single-molecule analysis. , 2022, Nanoscale.

[9]  Son Tung Ngo,et al.  Effect of Cholesterol Molecules on Aβ1-42 Wild-Type and Mutants Trimers , 2022, Molecules.

[10]  H. Hsieh-Li,et al.  Flavones 7,8-DHF, Quercetin, and Apigenin Against Tau Toxicity via Activation of TRKB Signaling in ΔK280 TauRD-DsRed SH-SY5Y Cells , 2021, Frontiers in Aging Neuroscience.

[11]  Yu Zou,et al.  Unraveling the Influence of K280 Acetylation on the Conformational Features of Tau Core Fragment: A Molecular Dynamics Simulation Study , 2021, Frontiers in Molecular Biosciences.

[12]  J. Loureiro,et al.  Influence of in vitro neuronal membranes on the anti-amyloidogenic activity of gallic acid: Implication for the therapy of Alzheimer's disease. , 2021, Archives of biochemistry and biophysics.

[13]  D. A. Bosco,et al.  Mouse closed head traumatic brain injury replicates the histological tau pathology pattern of human disease: characterization of a novel model and systematic review of the literature , 2021, Acta Neuropathologica Communications.

[14]  Sairam S. Mallajosyula,et al.  Phosphorylation-Induced Structural Reorganization in Tau-Paired Helical Filaments. , 2021, ACS chemical neuroscience.

[15]  C. White,et al.  Chronic Traumatic Encephalopathy (CTE)-Type Neuropathology in a Young Victim of Domestic Abuse. , 2021, Journal of neuropathology and experimental neurology.

[16]  Guanghong Wei,et al.  Liquid-Liquid Phase Separation of Tau Protein Is Encoded at the Monomeric Level. , 2021, The journal of physical chemistry letters.

[17]  D. Eliezer,et al.  Fisetin inhibits tau aggregation by interacting with the protein and preventing the formation of β-strands. , 2021, International journal of biological macromolecules.

[18]  R. Wennberg,et al.  Association of Position Played and Career Duration and Chronic Traumatic Encephalopathy at Autopsy in Elite Football and Hockey Players , 2021, Neurology.

[19]  Kevin F. Bieniek,et al.  The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy , 2021, Journal of neuropathology and experimental neurology.

[20]  Son Tung Ngo,et al.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. , 2021, Chemical reviews.

[21]  S. Ramasamy,et al.  EGCG impedes human Tau aggregation and interacts with Tau , 2020, Scientific Reports.

[22]  A. McKee,et al.  The Neuropathology of Chronic Traumatic Encephalopathy: The Status of the Literature , 2020, Seminars in Neurology.

[23]  Bikash R. Sahoo,et al.  High-Throughput Screening at the Membrane Interface Reveals Inhibitors of Amyloid-β. , 2020, Biochemistry.

[24]  Guanghong Wei,et al.  Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting Aβ42 Protofibril. , 2020, ACS chemical neuroscience.

[25]  Junmei Wang,et al.  Tau R3-R4 Domain Dimer of the Wild Type and Phosphorylated Ser356 Sequences. I. In Solution by Atomistic Simulations. , 2020, The journal of physical chemistry. B.

[26]  N. Petrovsky,et al.  Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology , 2020, Neurobiology of Disease.

[27]  H. Lashuel,et al.  Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau , 2020, The Journal of Biological Chemistry.

[28]  Guanghong Wei,et al.  Critical nucleus of Greek-key-like core of α-synuclein protofibril and its disruption by dopamine and norepinephrine. , 2019, Physical chemistry chemical physics : PCCP.

[29]  S. Ghasemzadeh,et al.  Inhibition of Tau Amyloid Fibril Formation by Folic Acid: in-vitro and theoretical studies. , 2019, International journal of biological macromolecules.

[30]  N. Petrovsky,et al.  A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice , 2019, Scientific Reports.

[31]  Sharad Gupta,et al.  Nanobiocatalyst facilitated aglycosidic quercetin as a potent inhibitor of tau protein aggregation. , 2019, International journal of biological macromolecules.

[32]  M. Pereira,et al.  Interaction of natural compounds with biomembrane models: A biophysical approach for the Alzheimer's disease therapy. , 2019, Colloids and surfaces. B, Biointerfaces.

[33]  C. Suter,et al.  Chronic traumatic encephalopathy in two former Australian National Rugby League players , 2019, Acta Neuropathologica Communications.

[34]  Qiuchen Zheng,et al.  Inhibition of the Self-Assembly of Aβ and of Tau by Polyphenols: Mechanistic Studies , 2019, Molecules.

[35]  Alexey G. Murzin,et al.  Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules , 2019, Nature.

[36]  L. Meijer,et al.  Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation , 2019, Front. Neurol..

[37]  Guanghong Wei,et al.  Norepinephrine Inhibits Alzheimer's Amyloid-β Peptide Aggregation and Destabilizes Amyloid-β Protofibrils: A Molecular Dynamics Simulation Study. , 2019, ACS chemical neuroscience.

[38]  R. Dinarvand,et al.  Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer’s disease animal model by reducing Tau hyperphosphorylation , 2018, DARU Journal of Pharmaceutical Sciences.

[39]  D. Weaver,et al.  Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation , 2018, Front. Neurosci..

[40]  S. Moradi,et al.  Effective suppression of the modified PHF6 peptide/1N4R Tau amyloid aggregation by intact curcumin, not its degradation products: Another evidence for the pigment as preventive/therapeutic "functional food". , 2018, International journal of biological macromolecules.

[41]  C. Soto,et al.  Inhibition of protein misfolding and aggregation by natural phenolic compounds , 2018, Cellular and Molecular Life Sciences.

[42]  Hong Zhang,et al.  Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease. , 2018, ACS nano.

[43]  L. Buée,et al.  Atypical, non-standard functions of the microtubule associated Tau protein , 2017, Acta neuropathologica communications.

[44]  T. Walz,et al.  Discovery and characterization of stable and toxic Tau/phospholipid oligomeric complexes , 2017, Nature Communications.

[45]  D. Eisenberg,et al.  Structure-based inhibitors of tau aggregation , 2017, Nature Chemistry.

[46]  A. Saboury,et al.  Vitamin B12 Inhibits Tau Fibrillization via Binding to Cysteine Residues of Tau. , 2017, ACS chemical neuroscience.

[47]  Christine M Baugh,et al.  Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football , 2017, JAMA.

[48]  E. Gazit,et al.  Inhibition of the Aggregation and Toxicity of the Minimal Amyloidogenic Fragment of Tau by Its Pro-Substituted Analogues. , 2017, Chemistry.

[49]  Robin O Cleveland,et al.  Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model , 2017, Alzheimer's & Dementia.

[50]  W. Stewart,et al.  Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers , 2016, Journal of neuropathology and experimental neurology.

[51]  Seong Ae Bang,et al.  Neuropsychological, Metabolic, and GABAA Receptor Studies in Subjects with Repetitive Traumatic Brain Injury. , 2016, Journal of neurotrauma.

[52]  M. Choe The Pathophysiology of Concussion , 2016, Current Pain and Headache Reports.

[53]  Wayne A. Gordon,et al.  The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy , 2015, Acta Neuropathologica.

[54]  J. Monti,et al.  Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer's Amyloid β-Peptide Aggregation. , 2015, Angewandte Chemie.

[55]  Chadwick M. Hales,et al.  Late-stage CTE pathology in a retired soccer player with dementia , 2014, Neurology.

[56]  U. Sengupta,et al.  Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.

[57]  U. Sengupta,et al.  Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury , 2013, The Journal of Biological Chemistry.

[58]  D. Dougherty The cation-π interaction. , 2013, Accounts of chemical research.

[59]  L. Ji,et al.  Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid. , 2013, Biochemistry.

[60]  A. McKee,et al.  The spectrum of disease in chronic traumatic encephalopathy. , 2013, Brain : a journal of neurology.

[61]  Robin O Cleveland,et al.  Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model , 2012, Science Translational Medicine.

[62]  David Eisenberg,et al.  Atomic View of a Toxic Amyloid Small Oligomer , 2012, Science.

[63]  Douglas H. Smith,et al.  Widespread Tau and Amyloid‐Beta Pathology Many Years After a Single Traumatic Brain Injury in Humans , 2012, Brain pathology.

[64]  J. Terao,et al.  Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. , 2011, Free radical biology & medicine.

[65]  Jason T. Stevens,et al.  Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation , 2011, Nature.

[66]  Ruth Nussinov,et al.  Synergistic Interactions between Repeats in Tau Protein and Aβ Amyloids May Be Responsible for Accelerated Aggregation via Polymorphic States , 2011, Biochemistry.

[67]  J. Bailes,et al.  Chronic traumatic encephalopathy in a professional American wrestler , 2010, Journal of forensic nursing.

[68]  A. McKee,et al.  Mild traumatic brain injury: a risk factor for neurodegeneration , 2010, Alzheimer's Research & Therapy.

[69]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[70]  A. McKee,et al.  Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury , 2009, Journal of neuropathology and experimental neurology.

[71]  J. Simon,et al.  Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[72]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[73]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[74]  E. Mandelkow,et al.  Spectroscopic Approaches to the Conformation of Tau Protein in Solution and in Paired Helical Filaments , 2006, Neurodegenerative Diseases.

[75]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[76]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[77]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[78]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[79]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[80]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[81]  A T Tysvaer,et al.  Soccer injuries to the brain , 1991, The American journal of sports medicine.

[82]  Y. Ihara,et al.  The car☐yl third of tau is tightly bound to paired helical filaments , 1988, Neuron.

[83]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[84]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[85]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[86]  G. Will “Punch Drunk” , 1939 .